DDIT3 and diffuse large B-cell lymphoma: Transcriptome analyses unveiled two distinct cell-of-origin (COO) signatures in DLBCL, representing a germinal center B-cell (GCB) and an activated B-cell (ABC) subtype6,8, with an inferior outcome consistently reported for the ABC subtype in many trials applying CHOP or R-CHOP regimens to DLBCL patients8.